Emptyend post on other board16 Apr 2021 10:21
VFN Stocks
ADVFN
FREE - In Google Play
VIEW
Search Stock
Logged out default avatar
Login Register
Monitor
Quote
Charts
Trades
News
Financials
Toplists
Alerts
Portfolio
Level 2
Free BB
PBB
ADVFN Logo
Copyright © 2021 ADVFN plc
Switch to Desktop View
Scancell Share Chat - SCLP
Current Price
22.50
0.00
0.0%
Bid Price Offer Price
22.00 23.00
High Price Low Price Open Price
22.50 21.75 22.50
Shares Traded Last Trade Market Cap (m)
16,852 08:00:20 178
Scancell Share Discussion Threads
Next Page
Date Subject
16/4/2021
09:15 emptyend: New article in regional press today......https://www.expressandstar.com/news/Features/2021/04/16/west-midlands-at-the-forefront-in-the-fight-against-covid/QUOTE:In one of these schemes, Cobra is working with experts at Nottingham University on a 'universal' injection which could provide protection against all variants within a year.While the existing AstraZeneca and Moderna jabs target Covid's spike proteins, which are prone to mutate as they try to find ways of beating the immunity, the new jab will also target the core of the virus itself, which are less likely to change.Prof Lindy Durrant, of Nottingham University, says: "The chances both will mutate at the same time is unlikely. It doubles the chances you win over the virus."This means that it cannot only fight off all current mutations of the vaccine, it will only require minimal adjustment as new variants appear, giving the vaccine greater longevity.Professor Durrant, who is head of the university's spin-off company Scancell, says the next generation of vaccines needs to be better prepared to tackle the virus as it learns to evade the immune system."We have the advantage of learning from the inadequacies of the first generation of vaccines to make the second generation better," she says.Cobra is already producing batches of the Nottingham vaccine to test production and prepare for the trials.Business development director Alexandra Brownfield says the vaccine is "grown" inside cells in a bio-reactor. An 11-gallon 'soup' of cells and nutrients can produce "a few thousand doses" over four to six weeks.She says producing the first batch of vaccine is a thrill: "It's a really good feeling, but we are always thinking about the next batch."It's a high-pressure environment, so although it's a relief we're then thinking we've still got work to do with the next batch."Dr Cliff Holloway, chief executive of Scancell, says the Cobra team at Staffordshire is crucial to the development of the vaccine."Cobra has the expertise needed to produce clinical-grade plasmid at scale and we look forward to working with them to advance our vaccine and demonstrate its potential effectiveness," he says.
Sign In
Follow the stocks
